This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bioequivalence Study of Sertraline Hydrochloride 100mg Tablets Under Fed Conditions

This study has been completed.
Information provided by:
Ranbaxy Inc. Identifier:
First received: October 23, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted
The purpose of this study was to evaluate the relative bioavailability of the test formulation of sertraline 100 mg tablets with an already marketed reference formulation Zoloft® 100 mg tablets (Pfizer), under non-fasting conditions in healthy male and female adult subjects.

Condition Intervention
Healthy Drug: sertraline 100 mg tablets

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: A Study to Compare the Relative Bioavailability of Ranbaxy and Pfizer Formulation of Sertraline 100 mg Tablets in Healthy Adult Volunteers Under Fed Conditions.

Resource links provided by NLM:

Further study details as provided by Ranbaxy Inc.:

Primary Outcome Measures:
  • Bioequivalence

Enrollment: 36
Study Start Date: August 2005
Study Completion Date: October 2005
Primary Completion Date: September 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
sertraline 100 mg tablets of Ranbaxy
Drug: sertraline 100 mg tablets
Active Comparator: 2
Zoloft® 100 mg tablets
Drug: sertraline 100 mg tablets

Detailed Description:

This randomized, single-dose, two-way, crossover study was conducted to compare the relative bioavailability of two formulations of 100 mg sertraline hydrochloride tablets under non-fasting conditions. The study was conducted with 36 (34 completing) healthy adults in accordance with protocol No.

10540324 (Revision 0). In each study period, a single 100 mg dose was administered to the subjects following a standardized high fat breakfast preceded by an overnight fast of at least 10 hours. The test formulation was Ranbaxy Research Laboratory's Sertraline Hydrochloride 100 mg Tablets and the reference formulation was ZOLOFT® (sertraline hydrochloride) 100 mg Tablets Manufactured by Roerig (Division of Pfizer). The subjects received the test product in one study period and the reference product in the other period; the order of administration was according to the dosing randomization schedule. There was a 14-day interval between treatments.

Blood samples were collected pre-dose and at intervals over 144 hours after each dose. The plasma samples for all subjects completing both periods of the study were sent to Helen Fassoulas, B.Sc., Director of Operations, Warnex Bioanalytical Services Inc., 3885 boul Industriel, Laval, Quebec, H7LAS3 Canada, Telephone: 450-663-6724, ext. 438, FAX: 450-975-8111 for determination of sertraline plasma concentration.

Statistical analysis was performed by Yetta I. Wilbur, Biostatistician, Novum Pharmaceutical Research Services, 5900 Penn Avenue, Pittsburgh, PA 15206, USA, Telephone: 412-363-3300, Fax: 412-362-5783 to evaluate the relative bioavailability of the test formulation to that of the reference product.

A total of 36 healthy adult subjects.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males and females, 18-65 years of age (inclusive).
  • A body mass index (BMI) of 18-30 kg/m2 inclusive as measured and calculated according to Novum Standard Operating Procedures.
  • Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening.
  • Signed and dated informed consent form, which meets all criteria of current FDA regulations.
  • Female subjects of child bearing potential must either abstain from sexual intercourse or use a reliable method of contraception (e.g. condom with spermicide, IUD, hormonal contraceptives) for at least 30 days prior to dosing and during the duration of the study.

Exclusion Criteria:

  • If female, pregnant, lactating or likely to become pregnant during the study.
  • History of allergy or sensitivity to sertraline hydrochloride or other selective serotonin reuptake inhibitor's (SSRI's), or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study.
  • Significant history or current evidence of chronic infectious disease, system disorder or organ dysfunction.
  • Presence of gastrointestinal disease or history of malabsorption within the last year.
  • History of psychiatric disorders occurring within the last two years that required hospitalization or medication.
  • Presence of a medical condition requiring regular treatment with prescription drugs.
  • Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes within 30 days prior to dosing.
  • Use within 14 days of dosing, or anticipated use during the study, or for 14 days after the last dose of sertraline any monoamine oxidase inhibitors (MAOIs).
  • Receipt of any drug as part of a research study within 30 days prior to dosing.
  • Drug or alcohol addiction requiring treatment in the past 12 months.
  • Donation or significant loss of whole blood (480 ml or more) with/n 30 days or plasma within 14 days prior to dosing.
  • Positive test results for HIV, Hepatitis B surface antigen or Hepatitis C antibody.
  • Positive test results for drugs of abuse at screening.
  • Positive serum pregnancy test.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00778973

United States, Pennsylvania
Novum Pharmaceutical Research Services
Pittsburgh,, Pennsylvania, United States, 15206
Sponsors and Collaborators
Ranbaxy Laboratories Limited
  More Information

Additional Information:
Responsible Party: Dr. Tausif Monif, Ranbaxy Research Labs Identifier: NCT00778973     History of Changes
Other Study ID Numbers: 10540324
Study First Received: October 23, 2008
Last Updated: October 23, 2008

Keywords provided by Ranbaxy Inc.:
Bioequivalence sertraline 100 mg tablets under fed conditions

Additional relevant MeSH terms:
Nutrition Disorders
Antidepressive Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs processed this record on September 20, 2017